US based developer of injectable drug delivery systems Unilife Corporation (ASX:UNS, NASDAQ:UNIS) has inked a 15-year commercial supply deal for wearable injectors with Sanofi.
Under the deal Unilife will be the sole provider of wearable injectors for all of Sanofi's large dose volume drugs, excluding insulins.
The agreement will also allow Sanofi to make Unilife’s wearable injectors available to its partners for use with applicable molecules under joint collaborations.
Unlilife has also granted Sanofi non-exclusive access to its wearable injector technology during the agreement and Unilife maintains the right to enter into other supply agreements.
Unlilife expects to start generating revenue from Sanofi this financial year from an upfront payment, customization programs and initial commercial sales.
Chairman and CEO Alan Shortall says Unilife’s wearable injectors are poised to generate substantial revenue and growth moving forward.
Unilife Corporation reported a net loss of $61.5 million in the 2014 financial year.
